Lantern Pharma (NASDAQ:LTRN) Announces Quarterly Earnings Results

Lantern Pharma (NASDAQ:LTRN) released its quarterly earnings results on Monday. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.10, FiscalAI reports.

Here are the key takeaways from Lantern Pharma’s conference call:

• Management highlighted a planned FDA Type C meeting for LP-300 (mid-May 2026) proposing protocol amendments to focus on EGFR exon 21 L858R patients, extend treatment cycles to eight, and convert to a single-arm Simon two-stage design to address changing standards of care.
• LP-184 reported encouraging Phase I data (63 patients) with a 48% clinical benefit rate at therapeutic doses, an established RP2D, biomarker-linked activity in DNA damage repair mutations, and planned precision trials in TNBC, NSCLC (KEAP1/STK11), and bladder cancer.
• Wholly-owned subsidiary Starlight/STAR-001 received IND clearance for pediatric CNS trials plus multiple Rare Pediatric Disease and Orphan Drug designations, creating potential for several FDA Priority Review Vouchers as non-dilutive value drivers.
• Lantern is commercializing its RADR/agentic AI product withZeta (AI Center of Excellence in India, 25+ beta partners, multi-tier subscription model) which management says could be a material long-term revenue stream but remains early and unproven.
• Financially, the company had ~$10.1M in cash as of 12/31/25 and expects runway only to roughly late July–mid?September 2026, stating it will need to raise substantial additional funding in the near term.

Lantern Pharma Trading Up 10.9%

Shares of Lantern Pharma stock opened at $1.37 on Wednesday. The firm has a market capitalization of $15.32 million, a PE ratio of -0.87 and a beta of 1.53. Lantern Pharma has a twelve month low of $1.11 and a twelve month high of $5.74. The firm’s 50-day moving average price is $2.65 and its 200 day moving average price is $3.35.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers acquired a new position in Lantern Pharma during the 4th quarter worth about $37,000. XTX Topco Ltd purchased a new position in Lantern Pharma in the 2nd quarter valued at approximately $40,000. CIBC Private Wealth Group LLC purchased a new position in Lantern Pharma in the fourth quarter valued at $47,000. Two Sigma Investments LP purchased a new stake in Lantern Pharma during the 3rd quarter worth about $70,000. Finally, Susquehanna International Group LLP acquired a new stake in Lantern Pharma in the third quarter valued at approximately $170,000. Institutional investors and hedge funds own 28.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lantern Pharma in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.